Any current/future new fundraising through debt or equity?

The management mentioned a planned capital raise (QIP - Qualified Institutional Placement) as a precursor to the merger process with Dhanuka Lab (DLL). The merger process will start soon and may take 12-18 months, with the share swap ratio approval expected in the next three months. There is no specific mention of new debt fundraising in the transcript. The capital raise is linked to the merger timing but details on quantum or timing are not elaborated. Overall, no explicit detailed plans for immediate fundraising through debt or equity outside the QIP related to merger were disclosed.

Any current/future capex/capital investment/strategic investment?

New sterile facility was successfully commissioned in early August 2023; benefits expected in upcoming quarters. Expansion of oral capacities is underway with expected operationalization by March 2024 to support continued growth. Land acquisition and CLU applications ongoing for the PLI project in Jammu; pilot plant setup is near completion. After completion of 7-ACA investment, plans include backward integration focused on advanced intermediates, reducing import dependence on China. Continuous normal capex is being done for plant upgradation and process improvements to maintain state-of-the-a

Future growth expectations in sales/revenue/volumes?

The company reported a strong Q1 FY24 revenue growth of 40% YoY, with INR182.9 crores revenue. Oral capacity utilization increased from ~65-70% to ~80%, driving volume growth; this level is expected to sustain. Sterile facility utilization remains high (~90-95%) but sterile contribution is flat; new sterile facility commissioned in August 2023 expected to boost sterile sales starting Q3 and full impact from Q4 FY24. Growth rate likely to moderate to 20-25% CAGR over FY24, lower than the Q1 spike. The company is pursuing new customers and reviving old ones across existing markets; no major new

Future growth expectations in earnings/operating earnings/profits/EPS?

Management expects a growth rate of around 20-25% CAGR in revenues for the full year FY24, moderating from the strong 40% growth seen in Q1. EBITDA margin is targeted to improve gradually, with an estimated 100 basis points increase annually, aiming for low to mid-teens percentages. Despite higher sales, operating expenses have remained flat, indicating operational efficiency gains. New sterile facility commissioned in August 2023 is expected to contribute from Q3 onwards, boosting sterile product sales. Oral capacity utilization improved to about 80%, driving growth; expansion of oral capacit

Current/ Expected Orderbook/ Pending Orders?

The transcript does not explicitly mention the current or expected order book or pending orders for Orchid Pharma Limited. Management discusses capacity utilization, with sterile facilities fully utilized and oral capacities increasing to about 80%. Growth is driven by increased utilization of oral capacities and a steady sterile business. New sterile facility commissioned in August 2023 is expected to contribute from Q2 onwards. Discussions mention large single consignments impacting quarterly numbers unpredictably, suggesting fluctuating order sizes rather than a fixed order book. No quantif

Orchid Pharma LtdQ1 FY24Pharmaceuticals & Biotechnology

Orchid Pharma Ltd Q1 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹893.5P/E: 296.4Market Cap: ₹5.4K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 2

The company reported a strong Q1 FY24 revenue growth of 40% YoY, with INR182.9 crores revenue.
Oral capacity utilization increased from ~65-70% to ~80%, driving volume growth; this level is expected to sustain.
Sterile facility utilization remains high (~90-95%) but sterile contribution is flat; new sterile facility commissioned in August 2023 expected to boost sterile sales starting Q3 and full impact from Q4 FY24.
Growth rate likely to moderate to 20-25% CAGR over FY24, lower than the Q1 spike.
The company is pursuing new customers and reviving old ones across existing markets; no major new markets but gaining share in emerging markets (Vietnam, Bangladesh, Pakistan).
Capacity expansions, especially oral capacities operational by March 2024, will support sustained growth.
Long-term growth drivers include new product development, operational efficiencies, and expansion in advanced intermediates production.

Margin guidance

Category 3

Management expects a growth rate of around 20-25% CAGR in revenues for the full year FY24, moderating from the strong 40% growth seen in Q1.
EBITDA margin is targeted to improve gradually, with an estimated 100 basis points increase annually, aiming for low to mid-teens percentages.
Despite higher sales, operating expenses have remained flat, indicating operational efficiency gains.
New sterile facility commissioned in August 2023 is expected to contribute from Q3 onwards, boosting sterile product sales.
Oral capacity utilization improved to about 80%, driving growth; expansion of oral capacities is planned to be operational by March 2024 to support future growth.
Tax expenses are minimal in near term due to carried-forward losses and unabsorbed depreciation.
Overall margin guidance places gross margins around 40% ± 2%, with sustainable EBITDA margins depending on asset utilization and market conditions.
Growth focus includes developing new products and expanding capacity over the next two years.

See what Orchid Pharma Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

The management mentioned a planned capital raise (QIP - Qualified Institutional Placement) as a precursor to the merger process with Dhanuka Lab (DLL).
The merger process will start soon and may take 12-18 months, with the share swap ratio approval expected in the next three months.
There is no specific mention of new debt fundraising in the transcript.
The capital raise is linked to the merger timing but details on quantum or timing are not elaborated.
Overall, no explicit detailed plans for immediate fundraising through debt or equity outside the QIP related to merger were disclosed.

Order book

The transcript does not explicitly mention the current or expected order book or pending orders for Orchid Pharma Limited.
Management discusses capacity utilization, with sterile facilities fully utilized and oral capacities increasing to about 80%.
Growth is driven by increased utilization of oral capacities and a steady sterile business.
New sterile facility commissioned in August 2023 is expected to contribute from Q2 onwards.
Discussions mention large single consignments impacting quarterly numbers unpredictably, suggesting fluctuating order sizes rather than a fixed order book.
No quantified or specific figures related to pending orders or order book are provided in the call.

See what Orchid Pharma Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

New sterile facility was successfully commissioned in early August 2023; benefits expected in upcoming quarters.
Expansion of oral capacities is underway with expected operationalization by March 2024 to support continued growth.
Land acquisition and CLU applications ongoing for the PLI project in Jammu; pilot plant setup is near completion.
After completion of 7-ACA investment, plans include backward integration focused on advanced intermediates, reducing import dependence on China.
Continuous normal capex is being done for plant upgradation and process improvements to maintain state-of-the-art facilities.
Post capital raise/QIP, merger process with Dhanuka Lab Limited (DLL) will restart, expected to take 12-18 months, enabling operational and strategic synergies.
R&D investments are increasing significantly due to new product development and research initiatives; specific budgets not disclosed yet.

Track Orchid Pharma Ltd — get its next earnings analysis in your feed

How does Orchid Pharma Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisOrchid Pharma Ltd

Rev 2Mar 3

See where Orchid Pharma Ltd sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Orchid Pharma Ltd rank in Pharmaceuticals & Biotechnology?

Compare Orchid Pharma Ltd against every Pharmaceuticals & Biotechnology company (Q1 FY24) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Orchid Pharma Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Bajaj Healthcare (Q2 FY27)
Operating Margin: Operating Margin = (EBITDA / Revenue from operations) × 100 = (2,770.29 / 14,791.49) × 100 ≈ 18.73% . Key results statement takeaways from Baj
Himalaya Nutravedics (Q2 FY27)
Reported revenue from operations for FY26: ₹4,306.8 lakhs, a year-on-year increase of 105.1% from ₹2,099.7 lakhs in FY25 (Page 22, 14, 5, 4). Key investor prese
Granules India (Q2 FY27)
Granules plans to invest about ₹2,000 crore in organic capital expenditure over the next 3-4 years. Key concall takeaways from Granules India Ltd's Q2 FY27…
Bajaj Healthcare (Q2 FY26)
For HYE (Half Year Ending) Sept 2025, Total Income reported is ₹299.28 crore. Key investor presentation takeaways from Bajaj Healthcare Ltd's Q2 FY26 investor p

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →